Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

The Lancet Neurology

Volumn 9, Issue 6, 2010, Pages 573-580

  Bxarone, Paolo ^a   Poewe, Werner ^b   Albrecht, Stefan ^c   Debieuvre, Catherine ^d   Massey, Dan ^e   Rascol, Olivier ^f   Tolosa, Eduardo ^g   Weintraub, Daniel ^h,i  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d BOEHRINGER INGELHEIM   (France)

^e BOEHRINGER INGELHEIM LTD   (United Kingdom)

^f CNRS   (France)

^g CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ E education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; PRAMIPEXOLE;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; EUROPE; FATIGUE; GERIATRIC DEPRESSION SCALE; HALLUCINATION; HUMAN; IMPULSE CONTROL DISORDER; INSOMNIA; MAJOR CLINICAL STUDY; MOTOR DYSFUNCTION; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SOUTH AFRICA; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; VERTIGO;

AGED; ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; DEPRESSIVE DISORDER; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; DYSKINESIAS; EUROPE; FEMALE; HUMANS; MALE; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SOUTH AFRICA; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952545893     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(10)70106-X     Document Type: Article

References (41)

1. Reijinders J.S., Ehrt U., Weber W.E., Aarsland D., and Leentjens A.F. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 23 (2007) 183-189
2. Schrag A. Quality of life and depression in Parkinson's disease. J Neurol Sci 248 (2006) 151-157
3. Cummings J.L. Depression and Parkinson's disease: a review. Am J Psychiatry 149 (1992) 443-454
4. Pankratz N., Marder K.S., Halter C.A., et al. Clinical correlates of depressive symptoms in familial Parkinson's disease. Mov Disord 23 (2008) 2216-2223
5. Remy P., Doder M., Lees A., Turjanski N., and Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128 (2005) 1314-1322
6. Ghazi-Noori S., Chung T.H., Deane K., Rickards H., and Clarke C.E. Therapies for depression in Parkinson's disease. Cochrane Database Syst Rev 3 (2003) CD003465.
7. Weintraub D., Morales K.H., Moberg P.J., et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 20 (2005) 1161-1169
8. Goetz C.G., Poewe W., Rascol O., and Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 20 (2005) 523-539
9. Devos D., Dujardin K., Poirot I., et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 23 (2008) 850-857
10. Menza M., Dobkin R.D., Marin H., et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 72 (2009) 886-892
11. Rektorova I., Rektor I., Bares M., et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 10 (2003) 399-406
12. Kano O., Ikeda K., Kiyozuka T., et al. Beneficial effect of pramipexole for motor function and depression in Parkinson's disease. Neuropsychiatr Dis Treat 4 (2008) 707-710
13. Corrigan M.H., Denahan A.Q., Wright C.E., Ragual R.J., and Evans D.L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 11 (2000) 58-65
14. Chernoloz O., El Mansari M., and Blier P. Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology 34 (2009) 651-661
15. Willner P., Lappas S., Cheeta S., and Muscat R. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology 115 (1994) 454-462
16. Aiken C.B. Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry 68 (2007) 1230-1236
17. Maj J., Rogoz Z., Skuza G., and Kolodziejczyk K. Antidepressant effects of pramipexole a novel dopamine receptor agonist. J Neural Transm 104 (1997) 525-533
18. Barone P., Scarzella L., Marconi R., et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 253 (2006) 601-607
19. Leentjens A., Koester J., Fruh B., Shephard D.T.S., Barone P., and Houben J.J.G. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Clin Ther 31 (2009) 89-98
20. Schrag A., Barone P., Brown R.G., et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 22 (2007) 1077-1092
21. Hughes A.J., Ben-Shlomo Y., Daniel S.E., and Lees A.J. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 42 (1992) 1142-1146
22. Hoehn M.M., and Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 17 (1967) 427-442
23. Weintraub D., Oehlberg K.A., Katz I.R., and Stern M.B. Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. Am J Geriatr Psychiatry 14 (2006) 169-175
24. Weintraub D., Saboe K., and Stern M.B. Effect of age on geriatric depression scale performance in Parkinson's disease. Mov Disord 22 (2007) 1331-1335
25. Sheikh J.L., and Yesavage J.A. Geriatric depression scale (GDS): recent evidence and development of a shorter version. In: Brink T.L. (Ed). Clinical gerontology: a guide to asssessment and intervention (1986), The Haworth Press, New York, USA 165-173
26. Fahn S., Elton R.L., and UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S., Marsden C.D., Calne D.B., and Goldstein M. (Eds). Recent developments in Parkinson's disease (1987), Macmillan, Florham Park, USA 153-163
27. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
28. Guy W. Clinical global impression (CGI). ECDEU assessment manual for psychopharmacology (1976), US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Rockville, MD 218-222
29. Beck A.T., Ward C.H., Mendelson M., Mock J., and Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 4 (1961) 561-571
30. Leentjens A., Verhey F.R.J., Luijckx G.-J., and Troost J. The validity of the Beck depression inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov Disord 15 (2000) 1221-1224
31. Jenkinson C., Fitzpatrick R., Peto V., Greenhall R., and Hyman N. The Parkinson's disease questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 26 (1997) 353-357
32. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 16 (1990) 199-208
33. Snaith R.P., Hamilton M., Morley S., Humayan A., Hargreaves D., and Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 167 (1995) 99-103
34. Retherford R.D., and Choe M.K. Statistical models for causal analysis. Chapter 4. Path Analysis (1994), John Wiley and Sons, New York 93-118
35. Wise T.N., Meyers A.L., Desaiah D., Mallinckrodt C.H., Robinson M.J., and Kajdasz D.K. The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: a post hoc analysis of 2 trials. Prim Care Companion J Clin Psychiatry 10 (2008) 270-275
36. Visser M., Leentjens A.F., Marinus J., Stiggelbout A.M., and van Hilten J.J. Reliability and validity of the Beck depression inventory in patients with Parkinson's disease. Mov Disord 21 (2006) 668-672
37. Menza M., Dobkin R.D., Marin H., et al. The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. Mov Disord 224 (2009) 1325-1332
38. Dunlop B.W., and Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 64 (2007) 327-337
39. Fournier J.C., DeRubeis R.J., Hollon S.D., et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303 (2010) 47-53
40. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products in the treatment of Parkinson's disease. http://www.ema.europa.eu/pdfs/human/ewp/056395en.pdf (accessed March 15, 2010).
41. Shulman L.M., Gruber-Baldini A.L., Anderson K.E., Fishman P.S., Reich S.G., and Weiner W.J. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol 67 (2010) 64-70